12
Participants
Start Date
October 27, 2023
Primary Completion Date
April 30, 2027
Study Completion Date
January 31, 2030
Personalized Neoantigen DNA vaccine
The sites of immunization may be rotated for each of the immunizations.
Retifanlimab
Retifanlimab will be supplied by Incyte.
TDS-IM v 2.0 electroporation device
Each DNA vaccination will be 1 mL vaccine administered intramuscularly using an integrated electroporation administration system
RECRUITING
Washington University School of Medicine, St Louis
Collaborators (1)
Incyte Corporation
INDUSTRY
PapiVax Biotech, Inc.
OTHER
The Foundation for Barnes-Jewish Hospital
OTHER
Washington University School of Medicine
OTHER